Want to see SYBX full AI Analyst Report?
SYBX Stock Chart & Stats
$1.22
$0.02(1.41%)
At close: 4:00 PM EST
$1.22
$0.02(1.41%)
Day’s Range― - ―
52-Week Range$0.54 - $1.96
Previous CloseN/A
Volume234.00
Average Volume (3M)41.08K
Market Cap
$8.20M
Enterprise Value-$5.80M
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.53
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,696,641
10 Day Avg. Volume24,108
30 Day Avg. Volume41,078
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.16
Enterprise Value/Market Cap-0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetReported zero total debt materially lowers fixed financial obligations and interest exposure, giving management flexibility to allocate scarce cash to R&D or partnerships. Over a 2–6 month horizon this reduces bankruptcy and interest-cost risk versus leveraged peers.
Sharply Reduced Cash BurnOperating cash flow improvement to roughly -$3.3M TTM from much larger prior deficits reflects disciplined cost control and program prioritization. That durable reduction in burn lengthens runway and lowers near-term financing urgency, aiding execution of clinical milestones.
Platform-driven Business ModelSynlogic’s engineered living medicines platform creates a patentable, scalable approach to modulate metabolites with programmable microbes. This platform focus supports durable IP, repeatable R&D programs and partnership/licensing revenue paths beyond one-off product sales.
Bears Say
Near-zero Revenue BaseEssentially no recurring revenue leaves Synlogic dependent on collaboration timing, milestone receipts, or external financing to fund operations. Absence of commercial sales means revenue visibility and scalability of the business model remain unproven over the next several quarters.
Negative Free Cash Flow And Volatile BurnAlthough burn has improved, free cash flow remains negative and TTM FCF growth is sharply negative, indicating volatility. Persistent negative cash generation forces reliance on financing, which can be dilutive or constrain development pacing and strategic options medium-term.
Contracted Asset And Equity BaseA sharp contraction in assets and equity erodes the company’s financial buffer and signals prior heavy cash consumption. A smaller capital base reduces resilience to clinical setbacks, increases sensitivity to funding markets, and raises execution risk for multi-stage development.
Synlogic News
SYBX FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was $0.54 and its highest was $1.96 in the past 12 months.
What is Synlogic’s market cap?
Synlogic’s market cap is $8.20M.
When is Synlogic’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Synlogic’s earnings last quarter?
Currently, no data Available
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synlogic have?
Synlogic has 11,696,641 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synlogic?
Currently, no hedge funds are holding shares in SYBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Synlogic
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Aptevo Therapeutics
―
SeaStar Medical Holding
―
Cingulate Inc
―
Allarity Therapeutics
―
Ownership Overview
0.11% Insiders
0.04% Mutual Funds
0.20% Other Institutional Investors
99.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---